Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.
Dimitrakopoulos FI, Mountzios G, Christopoulos P, Papastergiou T, Elshiaty M, Daniello L, Zervas E, Agelaki S, Samantas E, Nikolaidi A, Athanasiadis I, Baka S, Syrigos K, Christopoulou A, Lianos E, Samitas K, Tsoukalas N, Perdikouri EI, Oikonomopoulos G, Kottorou A, Kalofonou F, Makatsoris T, Koutras A, Megalooikonomou V, Kalofonos H. Dimitrakopoulos FI, et al. Among authors: mountzios g. Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122728. doi: 10.1177/17588359221122728. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36105886 Free PMC article.
Cancer burden in adolescents and young adults in Europe.
Trama A, Stark D, Bozovic-Spasojevic I, Gaspar N, Peccatori F, Toss A, Bernasconi A, Quarello P, Scheinemann K, Jezdic S, Blondeel A, Mountzios G, Bielack S, Saloustros E, Ferrari A. Trama A, et al. Among authors: mountzios g. ESMO Open. 2023 Feb;8(1):100744. doi: 10.1016/j.esmoop.2022.100744. Epub 2023 Feb 6. ESMO Open. 2023. PMID: 36753992 Free PMC article.
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
Mountzios G, Dimopoulos MA, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou CA. Mountzios G, et al. Ann Oncol. 2009 Aug;20(8):1362-8. doi: 10.1093/annonc/mdn797. Epub 2009 May 20. Ann Oncol. 2009. PMID: 19457937 Free article. Clinical Trial.
Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.
Mountzios G, Aravantinos G, Alexopoulou Z, Timotheadou E, Matsiakou F, Christodoulou C, Laschos K, Galani E, Koutras A, Bafaloukos D, Linardou H, Pectasides D, Varthalitis I, Papakostas P, Kalofonos HP, Fountzilas G. Mountzios G, et al. Mol Clin Oncol. 2016 Feb;4(2):211-220. doi: 10.3892/mco.2015.693. Epub 2015 Dec 4. Mol Clin Oncol. 2016. PMID: 26893865 Free PMC article.
Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab.
Mountzios G, Kotoula V, Kolliou GA, Papadopoulou K, Lazaridis G, Christodoulou C, Pentheroudakis G, Skondra M, Koutras A, Linardou H, Razis E, Papakostas P, Chrisafi S, Aravantinos G, Nicolaou I, Goussia A, Kalogeras K, Pectasides D, Fountzilas G. Mountzios G, et al. ESMO Open. 2019 May 12;4(2):e000441. doi: 10.1136/esmoopen-2018-000441. eCollection 2019. ESMO Open. 2019. PMID: 31231556 Free PMC article.
Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment.
Linardou H, Kotoula V, Kouvatseas G, Mountzios G, Karavasilis V, Samantas E, Kalogera-Fountzila A, Televantou D, Papadopoulou K, Mavropoulou X, Daskalaki E, Zaramboukas T, Efstratiou I, Lampaki S, Rallis G, Res E, Syrigos KN, Kosmidis PA, Pectasides D, Fountzilas G. Linardou H, et al. Among authors: mountzios g. Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):531-541. doi: 10.21873/cgp.20155. Cancer Genomics Proteomics. 2019. PMID: 31659106 Free PMC article. Clinical Trial.
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G. Metro G, et al. Among authors: mountzios g. J Thorac Dis. 2019 Dec;11(12):4972-4981. doi: 10.21037/jtd.2019.12.23. J Thorac Dis. 2019. PMID: 32030213 Free PMC article.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. Friedlaender A, et al. Among authors: mountzios g. Acta Oncol. 2020 Sep;59(9):1058-1063. doi: 10.1080/0284186X.2020.1781249. Epub 2020 Jun 17. Acta Oncol. 2020. PMID: 32762415
121 results